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Glucocorticoids protect and enhance recovery of cultured
murine podocytes via actin filament stabilization.
Background. Nephrotic syndrome is a common kidney dis-
ease in both children and adults that is characterized by dra-
matic structural changes in the actin-rich foot processes of
glomerular podocytes. Although glucocorticoids are the pri-
mary treatment for nephrotic syndrome, neither the target cell
nor mechanism of action of glucocorticoids in nephrotic syn-
drome is known. For the last 30 years glucocorticoids have been
presumed to act by reducing the release of soluble mediators of
disease by circulating lymphocytes. In contrast, we hypothesized
that glucocorticoids exert their beneficial effects in nephrotic
syndrome by direct action on podocytes.
Methods. Cultured murine podocytes were treated with glu-
cocorticoids in the presence and absence of mifepristone (to
inhibit glucocorticoid-induced transcriptional activation) and
challenged using our previously reported in vitro model of
puromycin aminonucleoside (PAN)–induced podocyte injury,
as well as by direct disruption of actin filaments with latrun-
culin and cytochalasin. Cell viability, actin filament distribution,
total polymerized actin content, and actin-regulating guanine
triphosphatase (GTPase) activities were measured.
Results. We demonstrated that treatment of cultured murine
podocytes with the glucocorticoid dexamethasone both pro-
tected and enhanced recovery from PAN-induced injury.
Dexamethasone also increased total cellular polymerized actin,
stabilized actin filaments against disruption by PAN, latrunculin,
or cytochalasin, and induced a significant increase in the activity
of the actin-regulating GTPase RhoA.
Conclusion. These data suggest that, contrary to the current
therapeutic paradigm, the beneficial effects of glucocorticoids
in nephrotic syndrome may result, at least in part, from direct
effects on podocytes leading to enhanced actin filament stability.
Nephrotic syndrome is a common kidney disease in
both adults and especially among children, with an esti-
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mated incidence of two to seven new cases per 100,000
children annually [1]. Because of the frequent occurrence
and the significant morbidity associated with nephrotic
syndrome and its treatment, the mechanism(s) by which
nephrotic syndrome occurs remains among the most im-
portant unanswered questions in nephrology today. The
characteristic ultrastructural changes observed during
the development of nephrotic syndrome occur in the
kidney glomerulus, where the distal (foot) processes of
visceral epithelial cells (podocytes) retract and efface
(spread), resulting in displacement and disruption of the
specialized slit diaphragms that span the filtration slits
between foot processes [2–5]. Foot process effacement,
often with detachment from the underlying glomerular
basement membrane (GBM), correlates closely with the
development of proteinuria [3, 5, 6]. These alterations
in the highly differentiated morphology of podocytes
have also been closely associated with dramatic rear-
rangements of the actin filaments in foot processes [7,
8]. Recent studies have identified mutations in the genes
encoding podocyte proteins as responsible for some cases
of inherited forms of nephrotic syndrome [9–11], and
gene knockout experiments in mice have identified ad-
ditional podocyte molecules that are required for normal
glomerular function [12–14], together providing strong
evidence suggesting that nephrotic syndrome is funda-
mentally a disease of the podocyte. Despite these ma-
jor advances, however, relatively few data have been
reported describing the specific subcellular events that
occur within podocytes during the vast majority of cases
of nephrotic syndrome (i.e., steroid-sensitive idiopathic
and noninherited forms), or how these changes might be
regulated at the molecular level [4, 7, 15–18].
For the last 50 years, glucocorticoid therapy has re-
mained the primary treatment for nephrotic syndrome,
despite a lack of understanding of either the pathogen-
esis of nephrotic syndrome or the target cell or mech-
anism of action of glucocorticoids in this disease. In
1974 Shalhoub [19] first advanced the “soluble media-
tor hypothesis” that minimal-change nephrotic syndrome
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(MCNS) is a disorder of the immune system in which re-
lease of T-lymphocyte–derived circulating factor(s) re-
sults in the pathophysiologic changes associated with
nephrotic syndrome. This hypothesis has remained the
dominant paradigm for subsequent investigations into
the pathogenesis of nephrotic syndrome, and as a re-
sult, glucocorticoid therapy has been presumed to act in
nephrotic syndrome by repression of a T-lymphocyte–
mediated response. However, identification of a circu-
lating factor responsible for proteinuria in nephrotic
syndrome has remained elusive [20]. Several circulating
factors have been shown to induce proteinuria in exper-
imental animals, including several serum factors [21–23]
and a variety of cytokines [24]. However, none of the
identified factors have fully satisfied the criteria of being
(1) universally present in elevated levels in the serum or
urine of patients with MCNS in relapse, but not of pa-
tients in remission, and (2) able to induce proteinuria in
experimental model systems.
In contrast to the above therapeutic paradigm, re-
cent studies have shown that glucocorticoid receptors
are present in glomerular cells, including podocytes, and
translocate to the nucleus upon dexamethasone treat-
ment [25]. Glucocorticoids have also been shown to in-
crease the stability of actin filaments [26], increase actin
polymerization, and activate cytoskeleton-associated ki-
nases in glomerular mesangial cells [27]. Furthermore,
numerous studies have suggested a central role for the
actin cytoskeleton in regulating podocyte structure, as
well as acting as the critical cytoskeletal protein anchor-
ing the focal adhesion and slit diaphragm proteins that are
responsible for podocyte attachment to both the under-
lying GBM and to adjacent podocytes (reviewed in [28]).
Based on these findings, we hypothesized that the ben-
eficial therapeutic effects of glucocorticoids in nephrotic
syndrome are mediated, at least in part, by a direct effect
on podocytes leading to enhanced actin filament stabil-
ity. To begin to test this hypothesis, we designed a series
of studies to determine the ability of glucocorticoids to
provide direct protection and enhanced recovery from
injury in cultured podocytes, as well as the effect of glu-
cocorticoid treatment on the stability of podocyte actin
filaments and the potential role of actin-regulating gua-
nine triposphatase (GTPase) in these effects.
METHODS
Cell culture
The mouse podocyte cells used in this study were a con-
ditionally immortalized clonal cell line isolated from the
“Immortomouse” [29] and were the kind gift of Dr. Peter
Mundel (Albert Einstein College of Medicine, Bronx,
NY). NIH 3T3 murine fibroblast cells were obtained com-
mercially (ATCC #CRL-1658) (ATCC, Manassas, VA,
USA), and murine mesangial cells were the kind gift of
Dr. Hanna Abboud (University of Texas Health Center,
San Antonio, TX). Cells were cultured, and in the case
of mouse podocyte cells, differentiated, as previously de-
scribed [18]. Briefly, murine podocytes were cultured in
RPMI 1640 medium containing 10% fetal bovine serum
(FBS), 100 U/mL penicillin, and 100 lg/mL streptomycin
(Gibco-BRL, Rockville, MD, USA). Podocyte cultures
were expanded by growth in medium containing 10 U/mL
mouse interferon-c (INF-c) (Sigma Chemical Co., St.
Louis, MO, USA) at 33◦C with 100% relative humidity
and 5% CO2 atmosphere, and were induced to differen-
tiate by culture at 37◦C in medium without INF-c for 10
to 14 days.
Cell treatments
The in vitro puromycin aminonucleoside (PAN) model
of podocyte process retraction used for these studies
was performed as previously reported [18], with mod-
ifications for pre- and posttreatment with dexametha-
sone or other hormones. Briefly, cells were treated for
30 minutes with water-soluble dexamethasone, water-
soluble progesterone, or water-soluble b-estradiol at final
concentrations of 0.01 to 20 lmol/L with or without
20 lmol/L mifepristone (RU486) (all from Sigma Chem-
ical Co.) added directly to the culture medium. After
pretreatment, the culture medium was changed to fresh
medium or fresh medium containing 1.25 or 5.0 lg/mL
PAN (Sigma Chemical Co.) and cultured for up to 7 days.
In separate experiments podocytes were treated with
the actin cytoskeleton-disrupting agents latrunculin A
and cytochalasin D (Sigma Chemical Co.) at 0.2 lmol/L
(latrunculin A) or 2 lmol/L (cytochalasin D) concentra-
tions for 10 minutes at various times after pretreatment.
For recovery experiments, pretreatment was omitted,
and after 5 days of PAN treatment (when cellular in-
jury was apparent) the culture medium was changed
to medium containing various concentrations of dexam-
ethasone. Subconfluent mouse mesangial cells and NIH-
3T3 cells were similarly treated with dexamethasone and
PAN at concentrations markedly higher than those used
for podocytes.
Cell viability assays
Podocyte viability was measured using 3-[4, 5]di-
methylthiazol-2,5-diphenyltetrazolium bromide (MTT)
reduction as previously described [30]. Wells used for
the negative controls were not seeded with cells. Af-
ter treatments the culture medium was replaced with
200 lL/well of fresh medium, and then 50 lL/well of a 50
mg/mL MTT (Sigma Chemical Co.) solution was added
and the cells cultured for 4 hours. The MTT media so-
lution was then removed, and 200 lL/well of dimethyl
sulfoxide (DMSO) (Sigma Chemical Co.) was added
followed by the addition of 25 lL/well glycine buffer
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(0.1 mol/L glycine, 0.1 mol/L NaCl, pH 10.5). Finally, the
absorbance of each well was immediately read at 570 nm
in a spectrophotometric plate reader (SpectraMAX 250)
(Molecular Devices, Sunnyvale, CA, USA).
Phase contrast and fluorescence microscopy
The actin filaments of cells grown on glass coverslips
and treated as described above were labeled with Texas
Red-conjugated phalloidin (Molecular Probes, Eugene,
OR, USA), and images were collected by phase contrast
and fluorescence microscopy as previously described [18].
Phalloidin binding assays
Phalloidin binding was determined as previously de-
scribed [18] with a modification for normalization of
results to 4′,6-diamidino-2-phenylindole (DAPI) fluo-
rescence. Briefly, treated podocytes were fixed in 3.7%
paraformaldehyde phosphate-buffered saline (PBS) for
30 minutes, washed once with PBS, and incubated in 0.1%
saponin (Sigma Chemical Co.) in PBS containing a satu-
rating amount (0.4 lmol/L) of Oregon Green 488 phal-
loidin and 5 lg/mL DAPI (Molecular Probes) for 1 hour
at room temperature in darkness with gentle agitation.
Cells were then washed three times with 0.1% saponin in
PBS, DAPI fluorescence was read (excitation at 354 nm
and emission at 460 nm) with a fluorescence plate reader
(SpectraMAX GeminiEM) (Molecular Devices), and the
labeled phalloidin was extracted from cells into 1 mL of
methanol by agitation for 30 minutes in darkness. The
methanol extract was collected, clarified by centrifuga-
tion, and the fluorescence of a diluted aliquot measured
in an LS-50B luminescence spectrometer (Perkin Elmer
Analytical Instruments, Norwalk, CN, USA) with exci-
tation at 591 nm and emission measured at 608 nm. Lin-
ear regression analyses of Texas Red phalloidin standards
was used to derive absolute amounts of bound phalloidin
from each sample’s relative fluorescence values. These
values were then normalized to DAPI fluorescence to
yield a measure of total polymerized actin (F-actin) per
cell.
GTPase activity assays
The percentage of active vs. total Rac1, RhoA, or
cdc42 GTPase were determined through Western blot-
ting of total cell lysates vs. affinity purified protein us-
ing the ROK Rho-binding and p-21–associated kinase
(Pak) binding domains as previously described [31]. The
pGEX-ROK-BD vector containing the ROK Rho bind-
ing domain (ROK-BD))amino acids 941-1075) was a kind
gift from Dr. Kozo Kaibuchi (Nagoya University, Nagoya,
Japan), and pGEX-Pak-BD vector containing the Pak
binding domain (Pak-BD) (amino acids 67-150) was a
kind gift from Dr. Gary Bokoch (Scripps Research Insti-
tute, La Jolla, CA, USA). The glutathione S-transferase
(GST) fusion proteins encoded by these vectors were pu-
rified from transformed Escherichia coli strain BL21 by
binding to S-hexylglutathione-agarose and were stored
bound (GST-ROK-BD or GST-Pak-BD). Active GT-
Pases were isolated by affinity association with immo-
bilized fusion proteins. Treated podocytes were rinsed
with warm PBS and lysed on ice for 10 minutes in
buffer A [25 mmol/L Tris, pH 7.5, at 4◦C, 150 mmol/L
K acetate, 5 mmol/L ethylenediaminetetraacetic acid
(EDTA), 5 mmol/L ethyleneglycol tetraacetate (EGTA),
10 mmol/L dithiothreitol (DTT), 1% Triton X-100,
60 mmol/L n-octyl-D-glucopyranoside, 50 lmol/L buty-
lated hydroxytoluene, and a protease inhibitor cocktail].
The extract was clarified by centrifugation, mixed with
GST-ROK-BD to assay for RhoA activity or GST-Pak-
BD to assay for Rac1 or Cdc42 activity, and incubated at
4◦C for 1 hour on a rotator. The amount of immobilized
fusion protein required to capture all of the available
GTPase was determined empirically. The GST-ROK-
BD or GST-Pak-BD beads were washed three times in
buffer A without detergent or protease inhibitors. The
supernatants were combined, the unbound GTPase frac-
tion was precipitated by addition of trichloroacetic acid
(TCA) to 10%, and the precipitates were washed with
70% ethanol-acetone and dried. Proteins in the pre-
cipitate (unbound fraction) and bound to the washed
beads (bound fraction) were separated by sodium do-
decyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE), and transferred to polyvinylidine difluoride
(PVDF) membranes. Western blotting was performed
using 1 lg/mL anti-RhoA (26C4) (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) or 2 lg/mL anti-Rac1
or anti-Cdc42 primary antibodies (Santa Cruz Biotech-
nology), and horseradish peroxidase–conjugated anti-
mouse secondary antibody (Jackson Immunoresearch,
West Grove, PA, USA). Antibody binding was visual-
ized by enhanced chemiluminescence (ECL) (Amersham
Pharmacia Biotech, Piscataway, NJ, USA) as detected by
Biomax ML film (Kodak, Rochester, NY, USA). To de-
termine the ratio of bound to unbound GTPase, film im-
ages were digitized and the optical density of each band
was quantified with a Fluor-S MultiImager with Quantity
One 4.1 software (Bio-Rad Laboratories, Hercules, CA,
USA). Results of densitometric analyses were expressed
as bound (active) GTPase as a percent of total (bound +
unbound) GTPase.
Statistics
Results were analyzed for statistically significant dif-
ferences using Statview version 4.57 software (Abacus
Concepts, Berkeley, CA, USA) by Scheffe’s F test.
Comparisons with P values < 0.05 were considered sig-
nificant, and P values < 0.01 were separately noted.




Fig. 1. Dexamethasone pretreatment protects podocytes against
puromycin aminonucleoside (PAN)–induced injury. Cultured, differ-
entiated podocytes were treated for 30 minutes with vehicle (A to C)
or 1 lmol/L dexamethasone (D to F) and then cultured for a further
7 days in medium containing vehicle (A and D), 1.25 lg/mL PAN (B and
E), or 5.0 lg/mL PAN (C and F). Cells were then fixed and viewed by
fluorescence microscopy after staining with Texas Red phalloidin (bar
40 l).
RESULTS
Dexamethasone pretreatment protects podocytes against
PAN-induced injury
Differentiated podocytes in culture are broad, flat-
tened, have numerous cell processes containing actin fil-
aments, and typically contain a central group of thick,
well-defined actin stress fibers (Fig. 1A). We used a pre-
viously described protocol [18] to injure differentiated
podocytes with two different concentrations of PAN for
7 days: (1) 1.25 lg/mL, a treatment which induces an in-
crease in cell area, a loss of cell processes, and a partial
disruption of actin filaments (Fig. 1B), but does not sig-
nificantly reduce cell survival (Table 1), and (2) 5.0 lg/mL
PAN, which causes cells to retract, almost completely dis-
rupts the podocyte actin cytoskeleton (Fig. 1C), and sig-
nificantly lowers cell survival (Table 1). Podocytes treated
for 30 minutes with 1 lmol/L dexamethasone and cul-
tured in fresh medium for a further 7 days formed a nearly
continuous monolayer, contained more numerous and
thicker actin stress fibers (data not shown) (Fig. 1D), and
significantly more cells survived in culture than untreated
controls (Table 1). Podocytes pre-treated with 1 lmol/L
dexamethasone and subsequently treated for 7 days with
1.25 lg/mL PAN were almost indistinguishable from
cells receiving only dexamethasone treatment (Fig. 1E)
(Table 1), while cells pre-treated with a 100× lower con-
centration of dexamethasone (0.01 lmol/L) and subse-
quently treated for 7 days with 1.25 lg/mL PAN were
indistinguishable from vehicle-treated controls (data not
shown) (Table 1). Although treatment for 7 days with
5.0 lg/mL PAN alone induced retraction of podocytes,
a decrease in cell survival, and disruption of actin stress
fibers, these effects were almost completely prevented by
pretreatment of podocytes with 1 lmol/L dexamethasone
for 30 minutes prior to PAN treatment (Fig. 1F compared
to Fig. 1C) (Table 1). In addition, partial protection from
the effects of 5.0 lg/mL PAN treatment was afforded by
pretreatment with 0.1 lmol/L dexamethasone, while a
pretreatment with 0.01 lmol/L dexamethasone had no
apparent protective effect (data not shown) (Table 1).
These results demonstrate that glucocorticoid pretreat-
ment has a dramatic protective effect against the actin
cytoskeletal injury, cell retraction, and cell death induced
by PAN.
Dexamethasone enhances podocyte recovery
from PAN-induced injury
Cultured podocytes treated with 5.0 lg/mL PAN for
only 5 days and then transferred to fresh medium with-
out PAN for an additional 2 days exhibited the same re-
traction, detachment, and actin cytoskeletal disruption
as cells treated for a full 7 days in medium containing
PAN (data not shown). To assess the more clinically rel-
evant question of the ability of dexamethasone to en-
hance the recovery of podocytes from prior injury, we
treated cultured podocytes with 5.0 lg/mL PAN for 5 days
to induce injury, and then transferred the cells to fresh
medium (or medium containing dexamethasone) for an
additional 7 days of culture to permit recovery. During
the recovery period, podocytes cultured in medium alone
displayed partial recovery from PAN-induced retraction
and actin cytoskeletal disruption (compare Fig. 2A to
Fig. 1C), though the cells were significantly smaller than
uninjured controls (data not shown), and failed to reform
the robust network of actin stress fibers characteristic
of differentiated podocytes. However, cells did reform
some stress fibers and processes (visible in uppermost
cell in Fig. 2A). In contrast, podocytes treated with as
little as 0.01 lmol/L dexamethasone for 3 days follow-
ing PAN treatment recovered to a greater extent than
those recovering for 7 days in the absence of dexametha-
sone treatment (compare Fig. 2B to Fig. 2A) and after
7 days of culture in the presence of 0.01 lmol/L dexam-
ethasone, previously injured cells were almost indistin-
guishable from uninjured control cells (compare Fig. 2C
to Fig. 1A). These results demonstrate that dexamatha-
sone treatment, even at concentrations well below that
needed to provide a protective effect against subsequent
injury, can dramatically enhance podocyte recovery from
PAN-induced injury.
RU486 blocks dexamethasone-mediated protection and
enhanced recovery from podocyte injury
Treatment of cultured mouse podocyte cells with
20 lmol/L RU486, an inhibitor of glucocorticoid
receptor–mediated gene transcription [32], or with
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Table 1. 3-[4,5]dimethylthiazol-2,5-diphenyltetrazolium bromide (MTT) assay of podocyte survival
Pretreatmenta Treatmentb % Survivalc P valued P valuee
Vehicle Vehicle 100.0 ± 8.1 — —
Vehicle 1.25 lg/mL PAN 88.5 ± 6.8 0.997 —
Vehicle 5 lg/mL PAN 50.2 ± 3.7 0.001 —
0.01 lmol/L dexamethasone Vehicle 102.1 ± 8.1 >0.999 —
1 lmol/L dexamethasone Vehicle 152.3 ± 6.2 <0.001 —
1 lmol/L dexamethasone + RU486 Vehicle 82.0 ± 4.3 0.923 —
0.01 lmol/L dexamethasone 1.25 lg/mL PAN 99.4 ± 4.3 >0.999 0.998
1 lmol/L dexamethasone 1.25 lg/mL PAN 132.4 ± 4.3 0.185 0.008
0.01 lmol/L dexamethasone 5 lg/mL PAN 46.5 ± 6.2 <0.001 >0.999
1 lmol/L dexamethasone 5 lg/mL PAN 102.0 ± 7.4 >0.999 <0.001
1 lmol/L dexamethasone + RU486 5 lg/mL PAN 43.0 ± 5.0 <0.001 >0.999
PAN is puromycin aminonucleoside.
a30 minutes followed by medium change.
b7 days without change of medium.
cPercent of vehicle pretreatment and vehicle treatment control (N = 8). Mean ± SEM.
dVersus vehicle control by Scheffe’s F test.
eVersus same treatment without dexamethasone pretreatment by Scheffe’s F test.
1 lmol/L dexamethasone together with 20 lmol/L RU486
for 30 minutes had no effect on podocyte morphology or
actin cytoskeletal structure 7 days after treatment (com-
pare Fig. 3A and B to Fig. 1A). Treatment with RU486
also did not alter the cytotoxic effects of subsequent treat-
ment with either 1.25 (data not shown) or 5.0 lg/mL PAN
(compare Fig. 3C to Fig. 1C). However, pretreatment
with RU486 completely blocked the protective effect of
a 30-minute pretreatment with 1 lmol/L dexamethasone
against subsequent treatment with PAN (compare Fig. 3D
with Fig. 1F), and was also able to block the protective ef-
fect of pretreatment at concentrations as high as 10 lmol/l
dexamethasone (Fig. 3E). In addition, inclusion of RU486
with dexamethasone blocked the enhanced recovery af-
forded by dexamethasone after a prior PAN-induced in-
jury (compare Fig. 3F with Fig. 2C). Finally, while RU486
combined with dexamethasone in the absence of subse-
quent PAN treatment resulted in a modest but signifi-
cant decrease in cell survival, RU486 pretreatment also
completely prevented dexamethasone-induced protec-
tion against PAN-induced cell death (Table 1). These find-
ings demonstrate that both the dexamethasone-induced
protection and enhanced recovery from PAN-induced in-
jury are regulated by glucocorticoid receptor–mediated
activation of gene transcription, a process known to be
blocked by RU486.
Dexamethasone protects actin filaments against direct
disruption by latrunculin A or cytochalasin D
Treatment of cultured mouse podocyte cells for 10 min-
utes with 0.2 lmol/L latrunculin A or with 2.0 lmol/L
cytochalasin D caused cells to retract and dramatically
disrupted their actin filaments (Fig. 4A and B). Simi-
larly, podocytes treated with 1 lmol/L dexamethasone for
30 minutes and immediately treated with latrunculin A or
cytochalasin D were indistinguishable from cells treated
with latrunculin A or cytochalasin D alone (data not
shown). However, podocytes pretreated with 1 lmol/L
A B C
Fig. 2. Dexamethasone enhances podocyte recovery from puromycin
aminonucleoside (PAN)–induced injury. Podocytes were treated for
5 days with 5.0 lg/mL PAN followed by culture medium containing
vehicle alone for a further 7 days (A) or 0.01 lmol/L dexamethasone
for a further 3 days (B) or 7 days (C). Cells were then fixed and viewed
by fluorescence microscopy after staining with Texas Red phalloidin
(bar 40 l).
dexamethasone for 30 minutes and subsequently cultured
for as little as 12 hours in fresh medium were far more
resistant to latrunculin A– or cytochalasin D–induced
disruption of actin filaments (data not shown). More-
over, by 3 days after dexamethasone treatment podocytes
were almost entirely protected from both the retraction
and disruption of actin filaments induced by latrunculin
A or cytochalasin D (Fig. 4C and D), and this protec-
tion was still evident 7 days after pretreatment (data not
shown). Importantly, this dexamethasone-induced pro-
tection was also blocked by inclusion of 20 lmol/L RU486
in the pretreatment medium (Fig. 4E and F). These results
demonstrate that the protective effect of dexamethasone
treatment on podocytes is not specific for PAN-induced
injury, but is also highly effective against agents such as
latrunculin A or cytochalasin D that directly disrupt the
actin cytoskeleton.
Dexamethasone increases podocyte total polymerized
actin and protects against depolymerization induced by
PAN or latrunculin A
When normalized to DAPI fluorescence, a DNA bind-
ing fluorophore, the fluorescence from Oregon Green
phalloidin is a highly reproducible measure of the total




Fig. 3. RU486 blocks dexamethasone-mediated protection and en-
hanced recovery from podocyte injury. Podocytes were treated for
30 minutes with 20 lmol/L RU486 (A and C), 20 lmol/L RU486 +
1 lmol/L dexamethasone (B and D), or 20 lmol/L RU486 + 10 lmol/L
dexamethasone (E), followed by incubation in culture medium alone
(A and B) or 5.0 lg/mL puromycin aminonucleoside (PAN) (C to E)
for a further 7 days. Additional cells were first treated with 5.0 lg/mL
PAN for 5 days to induce injury, followed by culture in medium contain-
ing 20 lmol/L RU486 + 1 lmol/L dexamethasone for a further 7 days
(F). Cells were then fixed and viewed by fluorescence microscopy after
staining with Texas Red phalloidin (bar 40 l).
polymerized actin (F-actin) content normalized to cell
number. We used this assay to measure the effect on
cultured podocyte F-actin content of dexamethasone
treatment followed by 3 days of culture. The 3-day post-
dexamethasone treatment time point was selected based
on the results of our microscopy studies where at 3 days
we observed maximal protection from latrunculin A–
or cytochalasin D–induced actin filament disruption (see
above). Treatment of cultured mouse podoctye cells with
1 lmol/L dexamethasone for 30 minutes followed by
culture in medium without dexamethasone for 3 days
induced a significant increase in F-actin in podocytes
(Fig. 5A) (P < 0.0001 vs. control). However, this increase
in total cellular F-actin was not blocked by inclusion of




Fig. 4. Dexamethasone protects actin filaments against direct disrup-
tion by latrunculin A or cytochalasin D. Podocytes were treated for
30 minutes with vehicle (A and B), 1.0 lmol/L dexamethasone (C and
D), or 1.0 lmol/L dexamethasone + 20 lmol/L RU486 (E and F), fol-
lowed by culture in medium without dexamethasone for an additional
3 days. Cells were then treated with 0.2 lmol/L latrunculin A for 10 min-
utes (A, C, and E) or with 2 lmol/L cytochalasin D for 10 minutes (B, D,
and F), to disrupt actin filaments. Cells were then fixed and viewed by
fluorescence microscopy after staining with Texas Red phalloidin (bar
40 l).
Treatment of cultured mouse podocyte cells with
5 lg/mL PAN for 3 days resulted in a significant decrease
in podocyte F-actin content (Fig. 5B) (P < 0.0001 vs. con-
trol), and this decrease was prevented by pretreatment
with 1 lmol/L dexamethasone (Fig. 5B). In contrast to
the increase in F-actin induced by dexamethasone pre-
treatment, this protective effect of dexamethasone was
abolished by inclusion of 20 lmol/L RU486 in the pre-
treatment medium (Fig. 5B). In a similar experiment, dex-
amethasone pretreatment for 30 minutes also prevented
the decrease in F-actin induced 3 days later by treatment
with 0.2 lmol/L latrunculin A for 10 minutes (Fig. 5C). In-
clusion of RU486 with dexamethasone pretreatment also
almost completely abolished this protective effect against
the effects of latrunculin on F-actin (Fig. 5C). These re-
sults confirm that dexamethasone pretreatment can pre-
vent depolymerization of the podocyte actin cytoskeleton
induced by two mechanistically distinct forms of injury,
and that this protection is dependent on dexamethasone-
induced activation of glucocorticoid receptor–mediated
gene transcription that can be blocked by RU486.
Glucocorticoid-induced protection is relatively specific
for murine podocytes
In light of the dramatic protective effects of dexam-
ethasone, one fundamental question was whether these
effects represent a generalized cellular or a podocyte-
specific response. To address this question, cultured
murine NIH 3T3 fibroblast cells and murine mesangial
cells were both treated with dexamethasone and their
resistance to subsequent PAN-induced injury analyzed.
Both murine mesangial cells and NIH 3T3 cells were


















































Fig. 5. Dexamethasone (DEX) increases
podocyte total polymerized actin and
protects against depolymerization-induced
by puromycin aminonucleoside (PAN) or
latrunculin A (LAT). Podocytes were treated
with vehicle alone (CON), 1 lmol/L dex-
amethasone, 20 lmol/L RU486, or 1 lmol/L
dexamethasone + 20 lmol/L RU486 for
30 minutes, followed by transfer to medium
alone (A and C) or medium containing
5.0 lg/mL PAN (B) for 3 days. Some cells
were then treated with 0.2 lmol/L latruculin
A for 10 minutes (C). Quantitative phalloidin
binding assays were then performed, and
the results normalized to 4′,6-diamidino-
2-phenylindole (DAPI) fluorescence (cell
number) to yield a measure of total F-actin
per cell (N = 6 samples/treatment). ∗P <
0.05; ∗∗P < 0.01 vs. control; ++P < 0.05 vs.
dexamethasone. Mean ± SEM.
A B C D
HGFE
Fig. 6. Glucocorticoid-induced protection is
relatively specific for murine podocytes.
Murine mesangial cells (A to D) and NIH 3T3
murine fibroblasts (E to H) were treated for
30 minutes with medium containing vehicle
alone (A, C, E, and G) or 20 lmol/L dexam-
ethasone (B, D, F, and H), and then cultured
for a further 7 days in fresh medium contain-
ing vehicle alone (A, B, E, and F), or 20 lg/mL
puromycin aminonucleoside (PAN) (C, D, G,
and H). Cells were then fixed and viewed by
fluorescence microscopy after staining with
Texas Red phalloidin (bar 40 l).
seeded at low density and formed a near-confluent cul-
ture after 7 days (Fig. 6A and E, respectively). Pre-
treatment for 30 minutes with 20 lmol/L dexamethasone
followed by further culture in medium containing vehi-
cle alone for 7 days had no detectable effect on either
murine mesangial cells or NIH 3T3 morphology, actin
filament structure, or cell number (Fig. 6C and G). Treat-
ment of both NIH 3T3 and murine mesangial cells for
7 days with 20 lg/mL PAN (the concentration required
to induce injury comparable to that seen in podocytes at
5 lg/mL) resulted in a decrease in actin filament stain-
ing and cell number (Fig. 6B and F) (data not shown).
In contrast to podocytes, however, pretreatment of these
cells with as much as 20 lmol/L dexamethasone had no
effect on the subsequent injury induced by PAN in NIH
3T3 cells (Fig. 6H), and only a modest protective effect on
murine mesangial cells (Fig. 6D). These results demon-
strate that the protective effect of dexamethasone against
subsequent PAN injury is at least relatively specific for
murine podocytes, and that even 20× higher concentra-
tions of dexamethasone in other murine-cultured cells
has notably less effect on their morphology and actin
cytoskeleton.
Steroid-induced podocyte protection is highly specific to
glucocorticoids
Another fundamental question about the protective
effects of dexamethasone was whether its protective ef-
fects are reflective of all steroid hormones or instead are
specific for glucocorticoids, the class of steroid hormone
used to treat patients with nephrotic syndrome. To ad-
dress this question, a direct comparison was made be-
tween the protective effects of glucocorticoids and two
other classes of steroid hormones. In baseline studies,
podocytes treated with progesterone or b-estradiol for
30 minutes at concentrations between 1 and 25 lmol/L
displayed no apparent changes in cell or actin filament
morphology during subsequent culture for as long as
7 days (Fig. 7A and C). More important, pretreatment
of podocytes with 25 lmol/L progesterone or b-estradiol
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A B C D
Fig. 7. Steroid-induced podocyte protection
is highly specific to glucocorticoids. Murine
podocytes were treated with 25 lmol/L pro-
gesterone (A and B) or b-estradiol (C and
D) for 30 minutes, and cultured for 7 days
in fresh medium containing vehicle alone (A
and C) or 5.0 lg/mL puromycin aminonucle-
oside (PAN) (B and D). Cells were then fixed
and viewed by fluorescence microscopy after
staining with Texas Red phalloidin (bar 40 l).
(25× higher than the dexamethasone concentration that
provided dramatic protection in podocytes) provided no
detectable protection from the cell retraction and actin
cytoskeletal disruption induced by subsequent treatment
with PAN (Fig. 7B and D). These findings confirm that the
protective effect of dexamethasone against PAN-induced
podocyte injury is highly specific to glucocorticoids com-
pared to other classes of steroid hormones.
Dexamethasone selectively increases Rho GTPase
activation but not expression
In an effort to identify the mechanism by which
dexamethasone exerted its protective effect against actin-
disrupting agents, we then determined if dexamethasone-
induced protection was associated with increases in the
activation of the actin-related GTPases RhoA, Rac1, or
Cdc42. The amount of Cdc42 protein that did not bind the
immobilized Pak peptide was below the level of detection
in both treated and control cell extracts, which indicated
that the vast majority (∼100%) of Cdc42 GTPase was
active in cultured podocytes (data not shown). We found
no significant change in the percentage of active Rac1
present in podocytes 3 days after dexamethasone treat-
ment compared to controls (Fig. 8). In contrast, the frac-
tion of activated RhoA protein was significantly greater in
dexamethasone-treated podocytes (28.7 ± 4.9%) than in
controls (9.8±1.5%) 3 days after treatment with 1 lmol/L
dexamethasone (P < 0.004). These results demonstrate
that dexamethasone, at the same concentration and time
that provide protection from podocyte injury and actin
disruption, can induce a significant activation of the actin-
related GTPase RhoA in cultured podocytes.
DISCUSSION
The question addressed by the present study was
whether glucocorticoids have a direct action on podocytes
resulting in protection from and/or amelioration of in-
jury. Our results demonstrate that glucocorticoids can
not only provide dramatic, direct protection of cultured
differentiated murine podocytes against injury, but can
also enhance recovery from prior podocyte injury. This
protection was evident against two mechanistically dis-
tinct types of podocyte injury, either induced by PAN, a
toxic molecule commonly used to induce experimental


















Fig. 8. Glucocorticoids induce an increase in RhoA guanine triphos-
phatase (GTPase) activation. Murine podocytes were treated with
1 lmol/L dexamethasone (DEX) for 30 minutes, cultured in fresh
medium for a further 3 days, and the relative amounts of GTP- (active)
and GDP-bound Rac1, RhoA, and Cdc42 GTPases were determined
by affinity chromatography and Western blotting. No results are shown
for Cdc42 since the amount of GDP-bound Cdc42 was too low to be de-
tected [∼100% GTP-bound Cdc42 in both control (CON) and dexam-
ethasone samples]. Results are expressed as percentage of GTP-bound
GTPase vs. total (N = 4 samples/treatment). ∗∗P < 0.01 vs. control.
Mean ± SEM.
podocyte actin filaments with latrunculin A or cytocha-
lasin D. This protection was completely dependent upon
activation of gene transcription via the glucocorticoid re-
ceptor, and was also found to be relatively specific for
podocytes and highly specific for glucocorticoids com-
pared to other steroid hormones. Additional mechanistic
studies found that dexamethasone induced a significant
increase in the activation of RhoA GTPase, a key regula-
tor of the actin cytoskeleton. These results demonstrate
that glucocorticoids have a dramatic positive effect on
podocytes in culture, and suggest that the beneficial ther-
apeutic effects of glucocorticoids in nephrotic syndrome
may be mediated, at least in part, by a direct action on
podocytes leading to enhanced actin filament stability.
Although a variety of drugs have been used to treat
children and adults with nephrotic syndrome, glucocorti-
coids have remained the primary treatment for nephrotic
syndrome for over 50 years [33]. Despite this, neither
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the target cell nor the mechanism of action of gluco-
corticoids in this disease have been identified. Due to
the absence of inflammatory cells in the glomeruli of pa-
tients with typical idiopathic nephrotic syndrome [34],
soluble factors, presumably secreted by circulating lym-
phocytes [35], have been implicated as causative agents in
this disease. However, despite extensive study for more
than 25 years, no consistent abnormalities in either se-
creted cytokines, the total number of T lymphocytes, or
the distribution of T lymphocytes among different subsets
have been identified to date (reviewed in [20]), though
clinical evidence still strongly suggests the involvement
of a circulating product of immune cells in nephrotic
syndrome. The known anti-inflammatory and immuno-
suppressive activities of glucocorticoids have historically
been taken as indirect evidence suggesting that they act
via suppression of an immune response. Recently, how-
ever, glomerular podocytes have been shown to contain a
functional glucocorticoid receptor [25], and several stud-
ies have demonstrated that glucocorticoids can alter the
expression of proteins in cultured podocytes [36, 37],
demonstrating that podocytes are capable of respond-
ing to glucocorticoids. More important, dexamethasone
was recently shown to partially attenuate an adriamycin-
induced increase in the permeability of podocyte cultures
to the passage of albumin [38], suggesting that dexam-
ethasone may protect murine podocytes against injury
induced by this compound as well.
A number of studies of nephrotic syndrome using ani-
mal models have reported indirect findings that are con-
sistent with our direct findings that glucocorticoids can
protect cultured podocytes against injury. Several stud-
ies of experimental nephrotic syndrome induced in rats
by injection of PAN demonstrated that glucocorticoids
can reduce the resulting proteinuria [39–41], and can
markedly attenuate podocyte foot process fusion [42]
and vacuolization [40]. In addition, glucocorticoids have
been shown to increase the expression of glomerular pro-
teins, including growth factors [43] and antioxidant en-
zymes [40]. These results, combined with our finding that
cultured murine podocytes are protected by dexametha-
sone from PAN-induced injury, provide clear initial evi-
dence to suggest that glucocorticoids may act in nephrotic
syndrome, at least in part, directly on the glomerular
podocyte.
Alterations in the structure of glomerular podocyte
foot processes are the histologic hallmark of nephrotic
syndrome, and several studies have closely linked the de-
velopment of nephrotic syndrome with actin disaggrega-
tion and an altered distribution of actin filaments within
podocytes [4, 7, 44]. Moreover, many of the podocyte
proteins identified by positional cloning from patients
with congenital nephrotic syndrome and gene knock-
out studies have a direct or close association with the
podocyte actin cytoskeleton [45–48]. The current results
provide additional evidence suggesting that regulation of
the podocyte actin cytoskeleton may be critical to the
mechanism of action of glucocorticoids in nephrotic syn-
drome. We found that treatment with dexamethasone
reduced the disruption of actin filaments induced by la-
trunculin A or cytochalasin D (Figs. 4 and 5C). Since la-
trunculin A sequesters actin monomers and cytochalasin
D is known to bind actin dimers and to cap the barbed
end of the actin filament [49], the apparent stabilization of
actin filaments by dexamethasone is either a result of an
increase in actin polymerization resulting in an increase
in the total pool of cellular F-actin, or due to a decrease
in the rate of actin depolymerization. We did observe an
increase in the total F-actin content of podocytes in re-
sponse to dexamethasone (Fig. 5A), but unlike the pro-
tective effect of dexamethasone against latrunculin A or
cytochalasin D disruption, the dexamethasone-induced
increase in podocyte F-actin was not inhibited by RU486,
an antagonist of glucocorticoid receptor–mediated gene
expression [50]. This discrepancy in RU486 effects sug-
gests that glucocorticoids may protect against latrunculin
A–induced disruption of podocyte actin filaments by de-
creasing the depolymerization rate of podocyte actin fila-
ments rather than by simply increasing total cellular actin.
In addition, the delay between dexamethasone treatment
and increased filament stability (∼12 hours), as well as the
sensitivity of this effect to inhibition by RU486, demon-
strate that dexamethasone stabilizes filaments by a ge-
nomic effect, presumably by increasing the expression of
a specific protein(s). However, our finding that RU486
does not inhibit the dexamethasone-induced increase in
podocyte F-actin strongly suggests that dexamethasone
also has nongenomic effects on podocytes that alter the
actin cytoskeleton.
We also observed that the actin-regulating GTPase
RhoA is activated in dexamethasone-treated podocytes
at the time after treatment when filaments are stabilized
against disruption (Fig. 8). Among other downstream tar-
gets, RhoA regulates members of the formin family of
proteins, which nucleate actin polymerization and weakly
cap barbed ends of filaments, and could contribute to
the stabilization we observed [51]. However, mice lack-
ing the gene for RhoGDI, which binds to and inhibits
the activity of RhoA, develop foot process effacement
and are proteinuric at birth [52]. While this result sug-
gests that elevated RhoA activity may disrupt normal
podocyte function, the mechanism of dexamethasone ac-
tion on podocytes leading to resistance to actin filament
disruption is likely to be more complex than simply in-
creasing the activity of RhoA.
The potential clinical relevance of these findings is
clearly dependent upon the relationship between the
dexamethasone concentrations used in the current stud-
ies and those achieved during glucocorticoid treat-
ment in humans. We found that the concentration of
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dexamethasone that provided almost complete protec-
tion against injury (1 lmol/L) is well within the range
of free prednisolone concentrations found in serum (ap-
proximately 1 lmol/L) from patients treated with a mod-
est dose (<0.5 mg/kg/day) of oral prednisolone [53],
and much less than those found after typical doses of
oral steroids for the clinical treatment of nephrotic syn-
drome (approximately 2 mg/kg/day) or after intravenous
pulse glucocorticoid therapy (500 to 1000 mg/day), where
serum concentrations can reach 60 to 200 lmol/L [54].
CONCLUSION
We found that glucocorticoids provided both direct
protection and enhanced recovery from injury to cul-
tured murine podocytes induced by an agent known to
induce nephrotic syndrome in rodents. Both of these
effects were highly sensitive to RU486, demonstrating
their dependence on glucocorticoid receptor–mediated
transcriptional activation. Although a glucocorticoid-
induced increase in total podocyte F-actin content was
not blocked by RU486, glucocorticoids also stabilized
actin filaments against disruption by latrunculin A and
cytochalasin D (which was blocked by RU486), and in-
duced significant activation of the actin-related GTPase
RhoA, suggesting that the increased stability of podocyte
actin filaments was not simply due to a glucocorticoid-
induced increase in total F-actin content. These data sug-
gest, in contrast to the current therapeutic paradigm, that
the beneficial effects of glucocorticoids in nephrotic syn-
drome may result, at least in part, from direct effects on
podocytes leading to enhanced actin filament stability.
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